openPR Logo
Press release

Antisense RNAi Therapeutics Market: Size, Share, and Trends Analysis

06-11-2024 01:23 PM CET | Health & Medicine

Press release from: Market Digits

Antisense RNAi Therapeutics Market: Size, Share, and Trends

The antisense RNA interference (RNAi) therapeutics market represents a burgeoning sector within the pharmaceutical industry, offering innovative treatments for a wide range of diseases by modulating gene expression at the post-transcriptional level. Antisense RNAi therapeutics leverage the RNA interference mechanism to target specific messenger RNA (mRNA) molecules, thereby inhibiting the production of disease-associated proteins.

As of [current year], the market for antisense RNAi therapeutics is experiencing rapid growth, driven by advancements in RNAi technology, expanding applications across therapeutic areas, and a growing pipeline of novel drug candidates. This overview provides insights into key aspects of the antisense RNAi therapeutics market, including market dynamics, trends, and recent developments.

๐——๐—ผ๐˜„๐—ป๐—น๐—ผ๐—ฎ๐—ฑ ๐—ฎ ๐—™๐—ฟ๐—ฒ๐—ฒ ๐˜€๐—ฎ๐—บ๐—ฝ๐—น๐—ฒ ๐—ฐ๐—ผ๐—ฝ๐˜† ๐—ผ๐—ณ ๐—ฅ๐—ฒ๐—ฝ๐—ผ๐—ฟ๐˜:
https://www.marketdigits.com/request/sample/4533

Major vendors in the global antisense RNAi therapeutics market: Alnylam Pharmaceuticals, Inc., Arbutus Biopharma, Astellas Pharma Inc., Benitec Biopharma Inc, Biogen, GSK plc, Ionis Pharmaceuticals, Merck KGaA, Novartis AG, Sanofi, Sarepta Therapeutics, Inc., Silence Therapeutics and Others.

Key Points

Market Size and Growth: The antisense RNAi therapeutics market has witnessed substantial growth in recent years, propelled by increasing investment in research and development, expanding applications in oncology, neurology, rare diseases, and other therapeutic areas, and the approval of several RNAi-based drugs. The market size is projected to reach [insert market size] by [future year], with a compound annual growth rate (CAGR) of [insert CAGR] during the forecast period.

Technology Overview: Antisense RNAi therapeutics encompass a diverse range of RNA-based molecules, including antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and microRNA (miRNA) mimics, designed to modulate gene expression through RNA interference. These molecules are engineered to target specific mRNA sequences associated with disease-causing genes, leading to the degradation of targeted mRNA or inhibition of protein translation, thereby attenuating disease pathology.

Therapeutic Applications: Antisense RNAi therapeutics hold promise for the treatment of various diseases, including genetic disorders, neurodegenerative diseases, infectious diseases, and cancer. Recent advancements in RNAi technology, delivery systems, and target identification have expanded the therapeutic potential of antisense RNAi drugs, driving clinical development efforts across multiple therapeutic areas.

Market Drivers: Several factors drive the growth of the antisense RNAi therapeutics market, including the increasing prevalence of chronic diseases, unmet medical needs in rare and genetic disorders, advancements in drug delivery technologies enabling targeted delivery of RNAi therapeutics to specific tissues or cell types, and the emergence of precision medicine approaches facilitating personalized treatment strategies.

Regulatory Landscape: Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) play a crucial role in overseeing the development and approval of antisense RNAi therapeutics. Regulatory pathways, such as the FDA's accelerated approval program and orphan drug designation, provide incentives and expedited pathways for the development of RNAi-based drugs targeting rare diseases and unmet medical needs.

Key Trends

Expansion of Oncology Pipeline: The oncology segment represents a major focus area for antisense RNAi therapeutics, with a growing number of drug candidates targeting oncogenes, tumor suppressor genes, and oncogenic signaling pathways. Advancements in target identification, RNAi delivery systems, and combination therapy approaches are driving the expansion of the oncology pipeline, with potential for improved efficacy and reduced toxicity compared to traditional chemotherapy.

Development of CNS-targeted Therapies: Antisense RNAi therapeutics hold promise for the treatment of central nervous system (CNS) disorders, including neurodegenerative diseases, spinal muscular atrophy (SMA), and Huntington's disease. Recent clinical advances, such as the approval of nusinersen for SMA and ongoing clinical trials in Alzheimer's disease and amyotrophic lateral sclerosis (ALS), underscore the potential of RNAi-based therapies in addressing unmet needs in CNS disorders.

Advancements in Delivery Technologies: Delivery remains a key challenge for RNAi therapeutics, particularly for achieving efficient and targeted delivery to specific tissues or cell types. Advancements in delivery technologies, such as lipid nanoparticles, conjugate-based delivery systems, and cell-targeting strategies, are facilitating improved pharmacokinetics, tissue penetration, and intracellular uptake of RNAi therapeutics, enhancing their therapeutic potential and expanding application areas.

Segmentations Analysis of Antisense RNAi Therapeutics Market: -

By Technology
RNA interference
siRNA
miRNA
Antisense RNA
Others

By Route of Administration
Intravenous (IV)
Subcutaneous
Inhalation delivery
Others

By Application
Cardiovascular Diseases (CVDs)
Genetic Disorders
Infectious Diseases
Neurodegenerative Disorders
Oncology
Renal Diseases
Respiratory Disorders
Others

Recent Developments

In July 2023, Alnylam Pharmaceuticals has announced a partnership with Roche to jointly develop and commercialize zilebesiran, an investigational RNAi therapeutic for hypertension in Phase 2. The collaboration aims to disrupt the global hypertension treatment paradigm, aligning with Alnylam's P5x25 strategy for impactful advancements in the field.

Recent Industry Developments (2024)

FDA Approval of Novel RNAi Drug: A leading pharmaceutical company received FDA approval for a novel antisense RNAi therapeutic targeting a rare genetic disorder. The drug, administered via subcutaneous injection, demonstrated significant efficacy in clinical trials, leading to improved disease outcomes and quality of life for patients with the rare condition.

Strategic Partnerships for Pipeline Expansion: Several biopharmaceutical companies announced strategic partnerships and collaborations to accelerate the development and commercialization of RNAi-based therapeutics. Collaborative efforts focus on leveraging complementary expertise in RNAi technology, drug discovery, and clinical development to advance pipeline candidates across various therapeutic indications.

Investment in RNAi Delivery Technologies: Venture capital firms and strategic investors continue to allocate significant funding to companies developing innovative RNAi delivery technologies. Investments aim to support the development of next-generation delivery systems capable of overcoming biological barriers, enhancing therapeutic efficacy, and enabling targeted delivery of RNAi therapeutics to specific disease sites.

๐—š๐—ฒ๐˜ ๐˜๐—ต๐—ถ๐˜€ ๐—ฟ๐—ฒ๐—ฝ๐—ผ๐—ฟ๐˜ ๐—ฎ๐˜ ๐—ฎ ๐—ฑ๐—ถ๐˜€๐—ฐ๐—ผ๐˜‚๐—ป๐˜:
https://www.marketdigits.com/request/discount/4533

In summary, the antisense RNAi therapeutics market is poised for continued growth and innovation, driven by advancements in RNAi technology, expanding therapeutic applications, and a robust pipeline of drug candidates. Key trends such as oncology pipeline expansion, CNS-targeted therapies, and advancements in delivery technologies are reshaping the landscape of RNAi-based drug development and positioning antisense RNAi therapeutics as promising treatment modalities for a wide range of diseases. As research efforts progress and clinical successes accumulate, antisense RNAi therapeutics are expected to play an increasingly prominent role in the future of precision medicine and personalized healthcare.

Contact Us:

1248 CarMia Way Richmond,
VA 23235, United States.
Phone: +1 510-730-3200
Email: sales@marketdigits.com
Website: https://www.marketdigits.com

About MarketDigits:

MarketDigits is one of the leading business research and consulting companies that helps clients to tap new and emerging opportunities and revenue areas, thereby assisting them in operational and strategic decision-making. We at MarketDigits believe that a market is a small place and an interface between the supplier and the consumer, thus our focus remains mainly on business research that includes the entire value chain and not only the markets.

We offer services that are most relevant and beneficial to the users, which help businesses to sustain themselves in this competitive market. Our detailed and in-depth analysis of the markets catering to strategic, tactical, and operational data analysis & reporting needs of various industries utilize advanced technology so that our clients get better insights into the markets and identify lucrative opportunities and areas of incremental revenues.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Antisense RNAi Therapeutics Market: Size, Share, and Trends Analysis here

News-ID: 3534360 • Views: โ€ฆ

More Releases for RNA

Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand. Browse 156 Market Data Tables and 112 Figures spread through 175โ€ฆ
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te โ€ฆ
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and mayโ€ฆ
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The โ€ฆ
With less than 4 weeks until SMiโ€™s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited. Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploringโ€ฆ
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme โ€ฆ
SMi Reports: In light of recent developments in the field of RNA Therapy, SMiโ€™s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year. Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improvedโ€ฆ
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018! Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He ledโ€ฆ
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion. One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems andโ€ฆ